---
layout: archive
title: "Publications"
permalink: /articles/
author_profile: true
---
You can also find my articles on <u><a href="https://scholar.google.com.tw/citations?user=ZkDKsLsAAAAJ&hl=en">my Google Scholar profile</a>.</u>


2023

* Lo MY, Tsai CH, Lin CC, Tien FM, Kuo YY, Lee WH, Peng YL, Liu MC, Tseng MH, Hsu CA, Chen JE, Lin LI, Sun HI, Chuang YK, Ko BS, Tang JL, Yao M, Chou WC, Hou HA, Tien HF. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023 May;98(5):760.
* Cheng CL, Yao CY, Huang PH, Yu CW, Fang WQ, Chuang WH, Wu SJ, Lin YJ, Hung YC, Tsai CH, Yu SC, Chou WC, Tien HF. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. Br J Haematol. 2023 Apr;201(1):75.
* Song YQ, Herve Tilly, Shinya Rai, Zhang HL, Jin Jie, Hideki Goto, Yasuhito Terui, Shin HJ, Kim WS, Cao JN, Feng JF, Hyeon-Seok Eom, Tae Min Kim, Tsai CH, Gau JP, Hideo Koh, Zhang LL, Song YP, Yang Y, Li W, Huang H, Kiyoshi Ando, Jeff P Sharman, Laurie H Sehn, Lilian Bu, Wang X, Jian YW, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial. Blood. 2023 Apr 20;141(16):1971.
* Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Ni SC, Yao M, Tseng MH, Liu MC, Tang JL, Sun HI, Chuang YK, Chou WC, Hou HA, Tien HF. Clinico-genetic and prognostic analyses of 716 patients with primary MDS and MDS/AML based on the 2022 International Consensus Classification. Am J Hematol. 2023 Mar;98(3):398.
* Tsai CH, Sun KJ, Lo MY, Tien FM, Kuo YY, Tseng MH, Peng YL, Chuang YK, Ko BS, Tang JL, Sun HI, Liu MC, Liu CW, Lin CC, Yao M, Chou WC, Hou HA, Tien HF. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J. 2023 Jan 4;13(1):4.
* Cheng CL, Yeh PT, Fang WQ, Ma WL, Hou HA, Tsai CH, Lin CP, Tien HF. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma. Cancer Med. 2023 Jan 5.

2022
* Lee WH, Lin CC, Tsai CH, Tseng MH, Kuo YY, Liu MC, Tang JL, Sun HI, Chuang YK, Chou WC, Hou HA, Tien HF. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. Am J Hematol. 2022 Dec;97(12):1589.
* Lee WH, Lin CC, Wang YH, Yao CY, Kuo YY, Tseng MH, Peng YL, Hsu CA, Sun HI, Chuang YK, Hsu CL, Tien FM, Tsai CH, Chou WC, Hou HA, Tien HF. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. Hematol Oncol. 2022 Nov 24.
* Wang YH, Yao CY, Lin CC, Chen CL, Hsu CL, Tsai CH, Hou HA, Chou WC, Tien HF. Higher RUNX1 expression levels are associated with worse overall and leukaemia-free survival in myelodysplastic syndrome patients. EJHaem. 2022 Aug 19;3(4):1209.
* Huang CW, Tsai CH, Lin CW. Optic neuropathy after chimeric antigen receptor T-cell therapy. J Formos Med Assoc. 2022 May;121(5):1012.
